Navigation Links
Immunovative Therapies Ltd. Introduces a Revolutionary Approach To Cancer Treatment
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire-iReach/ -- The most promising way to develop curative treatment that eliminates every cancer cell in a patient, says Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., would be by vaccinating the patient against the tumor.  The patient's own immune system, if correctly stimulated and manipulated, is capable of killing every last cancer cell. The concept of vaccine-based immune treatment of cancer is based on the body's own natural defense mechanism, which guards it against many diseases.  Vaccine immunotherapy has been shown to be an extremely effective treatment strategy for prevention of numerous potentially lethal infectious diseases.

Vaccines consisting of either killed or attenuated pathogens have revolutionized the public health system by thwarting the progression of many deadly infectious diseases, such as smallpox, poliomyelitis, rabies, diphtheria, cholera, typhoid fever, bubonic plague, measles, mumps, tetanus, and hepatitis B. Dr. Michael Har-Noy believes that the application of vaccination based therapy to cancer could similarly revolutionize cancer therapy.

However, Dr. Michael Har-Noy of Immunovative Therapies indicates that synthesizing effective cancer vaccines has proven to be much more difficult than developing vaccines for prevention of infectious diseases. Attempts to create successful immunotherapies in the form of cancer vaccines, despite decades of research and experimental trials, have yet to demonstrate significant curative potential in patients with malignant tumors.

The one dramatic exception to the failure of immunotherapy to produce significant tumor killing effects in cancer patients is the immunologic response that occurs in patients undergoing allogenic bone marrow/stem cell transplantation (BMT). The BMT is a proven curative therapy for certain hematological malignancies and also has shown some effectiveness in the treatment of solid tumors. The curative effect of the BMT is caused by the transplanted immune cells, which are derived from a healthy, tissue matched donor. The immune mediated anti-tumor activity of these transplanted cells is termed the graft vs. tumor (GVT) effect. At Immunovative Therapies, this mechanism has been analyzed in detail, and Immunovative Therapies has used the powerful cancer-killing GVT effect as the basis for the synthesis of an entirely new class of oncologic drugs.

Dr. Michael Har-Noy describes the GVT mechanism as the most powerful and most efficient tumor-killing process ever identified in the treatment of human cancer. Unfortunately, these same immune system T-cells which control the GVT effect also can cause an often lethal complication known as graft versus host disease (GVHD). This side effect occurs because the transplanted T-cells recognize both the normal and tumor cells of the recipient as foreign material and attack them both indiscriminately. Therefore, despite the fact that a BMT can eradicate solid as well as hematologic cancers, the often lethal toxicity of GVHD has prevented the wide spread application of BMT as a cancer treatment.

The powerful GVT immune mechanism observed in BMT recipients is capable of disabling a tumor's immunoavoidance capability, thus resulting in complete eradication of the cancer in many instances. The GVT effect has been shown to be able to cure cancer patients with large tumors, including patients with malignancies unresponsive to chemotherapy, radiation and other types of immunologic treatments.

Immunovative Therapies has developed a line of biologic products, based upon completely proprietary technology, which is engineered to produce, in a cancer patient, the same anti-tumor effect that has been shown to be curative in allogenic bone marrow transplant (BMT) procedures but without the potentially lethal toxicity associated with it. Dr. Michael Har-Noy of Immunovative Therapies hopes to soon begin a Phase II/III trial of these drugs in metastatic breast cancer patients.

About: Immunovative Therapies Ltd. is a biotech company in Israel. Under the direction of its founder and CEO, Dr. Michael Har-Noy, the company is developing and testing revolutionary new cancer treatments that, when brought to market, will likely spawn a new field of oncology.

Media Contact: Bethany Franklin, Optimizeup.com, 1-800-701-6787, support@optimizeup.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Immunovative Therapies Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
5. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
9. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):